IRS-1: Auditing the effectiveness of mTOR inhibitors

Research output: Contribution to journalShort surveypeer-review

62 Scopus citations


Rapamycin analogs that inhibit mTOR signaling have antitumor activity against certain lymphomas, but treatment of solid tumors has been less encouraging despite inhibition of mTOR function. Two recent papers give insight into the potential use of mTOR inhibitors. O'Reilly et al. provide evidence that poor tumor response to rapamycins is the result of relieving mTOR-mediated feedback inhibition of insulin receptor substrate 1, and activation of Akt-mediated survival. In the second paper, Kaper et al. address the impact of pathway activation on hypoxia-mediated downregulation of mTOR signaling, raising the possibility that rapalogs could selectively inhibit hypoxic cells.

Original languageEnglish (US)
Pages (from-to)153-155
Number of pages3
JournalCancer Cell
Issue number3
StatePublished - Mar 2006
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'IRS-1: Auditing the effectiveness of mTOR inhibitors'. Together they form a unique fingerprint.

Cite this